ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years

Frank A. López, Ann Childress, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner, Robert A. Lasser, John Shepski, Valerie Arnold

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To describe symptom rebound in children with ADHD treated with lisdexamfetamine dimesylate (LDX) or placebo. Method: During a 4-week, randomized, double-blind, placebo-controlled trial of LDX, parents/caregivers completed the Conners’ Parent Rating Scale–Revised: Short Form symptom rating scale throughout the day. Response, rebound, and emotional lability (EL) were assessed post hoc based on predefined criteria. Results: Most participants given LDX (n = 207) were responders throughout the day (50.7%-55.6%) versus placebo (n = 72; 11.1%-22.2%). A total of seven (3.4%) LDX participants showed rebound in the afternoon and/or evening versus seven (9.7%) with placebo. In both groups, most incidences of rebound occurred in the evening. EL (mean) was higher in LDX rebounders and nonresponders (range = 4.2-9.0) versus LDX responders (range = 1.3-1.6) and versus placebo rebounders (range = 0.7-1.9). Conclusion: ADHD symptom rebound occurred in few participants (3.3%) given LDX (accompanied by clinically significant EL). Overall, more participants given LDX versus placebo responded throughout the day.

Original languageEnglish (US)
Pages (from-to)52-61
Number of pages10
JournalJournal of Attention Disorders
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Placebos
Lisdexamfetamine Dimesylate
Caregivers
Parents
Incidence

All Science Journal Classification (ASJC) codes

  • Developmental and Educational Psychology
  • Clinical Psychology

Cite this

ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years. / López, Frank A.; Childress, Ann; Adeyi, Ben; Dirks, Bryan; Babcock, Thomas; Scheckner, Brian; Lasser, Robert A.; Shepski, John; Arnold, Valerie.

In: Journal of Attention Disorders, Vol. 21, No. 1, 01.01.2017, p. 52-61.

Research output: Contribution to journalArticle

López, FA, Childress, A, Adeyi, B, Dirks, B, Babcock, T, Scheckner, B, Lasser, RA, Shepski, J & Arnold, V 2017, 'ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years', Journal of Attention Disorders, vol. 21, no. 1, pp. 52-61. https://doi.org/10.1177/1087054712474685
López, Frank A. ; Childress, Ann ; Adeyi, Ben ; Dirks, Bryan ; Babcock, Thomas ; Scheckner, Brian ; Lasser, Robert A. ; Shepski, John ; Arnold, Valerie. / ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years. In: Journal of Attention Disorders. 2017 ; Vol. 21, No. 1. pp. 52-61.
@article{c7bcd0440c42484088e0eed1208df085,
title = "ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years",
abstract = "Objective: To describe symptom rebound in children with ADHD treated with lisdexamfetamine dimesylate (LDX) or placebo. Method: During a 4-week, randomized, double-blind, placebo-controlled trial of LDX, parents/caregivers completed the Conners’ Parent Rating Scale–Revised: Short Form symptom rating scale throughout the day. Response, rebound, and emotional lability (EL) were assessed post hoc based on predefined criteria. Results: Most participants given LDX (n = 207) were responders throughout the day (50.7{\%}-55.6{\%}) versus placebo (n = 72; 11.1{\%}-22.2{\%}). A total of seven (3.4{\%}) LDX participants showed rebound in the afternoon and/or evening versus seven (9.7{\%}) with placebo. In both groups, most incidences of rebound occurred in the evening. EL (mean) was higher in LDX rebounders and nonresponders (range = 4.2-9.0) versus LDX responders (range = 1.3-1.6) and versus placebo rebounders (range = 0.7-1.9). Conclusion: ADHD symptom rebound occurred in few participants (3.3{\%}) given LDX (accompanied by clinically significant EL). Overall, more participants given LDX versus placebo responded throughout the day.",
author = "L{\'o}pez, {Frank A.} and Ann Childress and Ben Adeyi and Bryan Dirks and Thomas Babcock and Brian Scheckner and Lasser, {Robert A.} and John Shepski and Valerie Arnold",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/1087054712474685",
language = "English (US)",
volume = "21",
pages = "52--61",
journal = "Journal of Attention Disorders",
issn = "1087-0547",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years

AU - López, Frank A.

AU - Childress, Ann

AU - Adeyi, Ben

AU - Dirks, Bryan

AU - Babcock, Thomas

AU - Scheckner, Brian

AU - Lasser, Robert A.

AU - Shepski, John

AU - Arnold, Valerie

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: To describe symptom rebound in children with ADHD treated with lisdexamfetamine dimesylate (LDX) or placebo. Method: During a 4-week, randomized, double-blind, placebo-controlled trial of LDX, parents/caregivers completed the Conners’ Parent Rating Scale–Revised: Short Form symptom rating scale throughout the day. Response, rebound, and emotional lability (EL) were assessed post hoc based on predefined criteria. Results: Most participants given LDX (n = 207) were responders throughout the day (50.7%-55.6%) versus placebo (n = 72; 11.1%-22.2%). A total of seven (3.4%) LDX participants showed rebound in the afternoon and/or evening versus seven (9.7%) with placebo. In both groups, most incidences of rebound occurred in the evening. EL (mean) was higher in LDX rebounders and nonresponders (range = 4.2-9.0) versus LDX responders (range = 1.3-1.6) and versus placebo rebounders (range = 0.7-1.9). Conclusion: ADHD symptom rebound occurred in few participants (3.3%) given LDX (accompanied by clinically significant EL). Overall, more participants given LDX versus placebo responded throughout the day.

AB - Objective: To describe symptom rebound in children with ADHD treated with lisdexamfetamine dimesylate (LDX) or placebo. Method: During a 4-week, randomized, double-blind, placebo-controlled trial of LDX, parents/caregivers completed the Conners’ Parent Rating Scale–Revised: Short Form symptom rating scale throughout the day. Response, rebound, and emotional lability (EL) were assessed post hoc based on predefined criteria. Results: Most participants given LDX (n = 207) were responders throughout the day (50.7%-55.6%) versus placebo (n = 72; 11.1%-22.2%). A total of seven (3.4%) LDX participants showed rebound in the afternoon and/or evening versus seven (9.7%) with placebo. In both groups, most incidences of rebound occurred in the evening. EL (mean) was higher in LDX rebounders and nonresponders (range = 4.2-9.0) versus LDX responders (range = 1.3-1.6) and versus placebo rebounders (range = 0.7-1.9). Conclusion: ADHD symptom rebound occurred in few participants (3.3%) given LDX (accompanied by clinically significant EL). Overall, more participants given LDX versus placebo responded throughout the day.

UR - http://www.scopus.com/inward/record.url?scp=85008690087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008690087&partnerID=8YFLogxK

U2 - 10.1177/1087054712474685

DO - 10.1177/1087054712474685

M3 - Article

VL - 21

SP - 52

EP - 61

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

SN - 1087-0547

IS - 1

ER -